Table 4.
Incidence of Adverse Events by Age Group
| 18–64 Years | 65–74 Years | ≥ 75 Years | ||||
|---|---|---|---|---|---|---|
| Pregabalin (n = 2,856) | Placebo (n = 1,602) | Pregabalin (n = 1,271) | Placebo (n = 682) | Pregabalin (n = 756) | Placebo (n = 342) | |
| Dizziness | 639 (22.4) | 113 (7.1) | 333 (26.2) | 45 (6.6) | 213 (28.2) | 33 (9.6) |
| Somnolence | 414 (14.5) | 78 (4.9) | 194 (15.3) | 27 (4.0) | 129 (17.1) | 17 (5.0) |
| Peripheral edema | 218 (7.6) | 62 (3.9) | 123 (9.7) | 26 (3.8) | 79 (10.4) | 7 (2.0) |
| Weight increase | 185 (6.5) | 21 (1.3) | 70 (5.5) | 11 (1.6) | 47 (6.2) | 1 (0.3) |
| Dry mouth | 134 (4.7) | 31 (1.9) | 69 (5.4) | 16 (2.3) | 43 (5.7) | 6 (1.8) |
| Constipation | 115 (4.0) | 27 (1.7) | 70 (5.5) | 23 (3.4) | 49 (6.5) | 13 (3.8) |
| Blurred vision | 86 (3.0) | 16 (1.0) | 48 (3.8) | 8 (1.2) | 41 (5.4) | 9 (2.6) |
| Balance disorder | 46 (1.6) | 4 (0.2) | 29 (2.3) | 2 (0.3) | 34 (4.5) | 1 (0.3) |
| Euphoric mood | 63 (2.2) | 4 (0.2) | 9 (0.7) | 0 | 8 (1.1) | 0 |
Number (percentage) of patients experiencing each adverse event. Adverse events with a risk difference for which the lower limit of the 95% CI was >1% (all-doses pregabalin) are shown.